PDE5 inhibition can reduce iNOS and Arg1 activity in MDSCs, thereby triggering antitumor response and T cell infiltration in preclinical models of colon cancer and breast cancer (145) or in patients with end-stage multiple myeloma (146). Here, ARG1 is linked to breast carcinoma.